Curis Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
12,322.00
18,728.70
58,981.00
60,411.00
53,317.00
32,575
Depreciation, Depletion & Amortization
141.50
155.10
160.80
193.00
235.00
177
Other Funds
3,144.90
1,886.30
28,025.80
22,530.00
5,450.00
3,835
Funds from Operations
9,035.60
16,687.40
30,794.40
37,688.00
47,632.00
28,563
Changes in Working Capital
503.90
125.40
903.60
1,877.00
723.00
1,502
Net Operating Cash Flow
9,539.60
16,812.70
29,890.80
35,811.00
48,355.00
30,065
Capital Expenditures
153.00
92.20
48.00
329.00
188.00
Sale of Fixed Assets & Businesses
-
1.80
23.80
-
-
Purchase/Sale of Investments
13,478.40
16,349.60
6,404.10
30,453.00
3,442.00
Net Investing Cash Flow
13,617.50
16,273.00
6,428.30
30,124.00
3,630.00
Issuance/Reduction of Debt, Net
-
1,587.20
4,162.80
4,273.00
21,551.00
Net Financing Cash Flow
20,000.90
1,304.40
61,662.90
1,366.00
64,235.00
Net Change in Cash
3,156.20
1,844.10
25,343.80
7,053.00
12,250.00
Free Cash Flow
9,692.60
16,905.00
29,938.80
36,140.00
48,543.00
Other Sources
13.90
13.90
-
-
-
Change in Capital Stock
20,262.40
282.80
65,825.70
2,907.00
42,684.00

About Curis

View Profile
Address
4 Maguire Road
Lexington Massachusetts 02421
United States
Employees -
Website http://www.curis.com
Updated 07/08/2019
Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.